REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness

HB 4762 REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness

US Congress 114th Congress

REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness
HB-4762

About HB-4762

REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness This bill amends the Public Health Service Act to require the Food and Drug Administration (FDA) to conditionally approve certain cellular therapeutic products without initiation of large-scale clinical trials. A conditionally approved cellular therapy may be marketed if certain conditions are met, including conditions on the source, processing, and function of the cells in the product.

  

Bill Texts

Introduced 03/17/2016

Weigh In

No votes yet!
Cast yours now to be the first.

Votes for: 0 Votes against: 0

Spread the Word!

Gettr Embed Code

Sponsors (5)

Rep. H. Morgan Griffith


Co-Sponsor

Rep. Mike Coffman


Co-Sponsor

Rep. F. James Sensenbrenner


Co-Sponsor

Rep. Dana Rohrabacher


Co-Sponsor

Rep. Mark Takai


Co-Sponsor

Track This Bill

Get notified when this bill is updated

Sponsors by party

     

Bill Sponsors

History

Referred To The Subcommittee On Health.

03/18/2016

Introduced In House

03/16/2016

Referred To The House Committee On Energy And Commerce.

03/16/2016

Subject(s)

Health Administrative Law And Regulatory Procedures Cell Biology And Embryology Department Of Health And Human Services Drug Safety, Medical Device, And Laboratory Regulation Organ And Tissue Donation And Transplantation